Impact of recurrence on employment, finances, and productivity for early-stage cancer patients and caregivers: US survey
The financial burden to patients, caregivers, healthcare systems, and society following early-stage cancer recurrence is substantial. Treatments that decrease recurrences can reduce this burden.
Authors
- Rutika Raina (ORCID: https://orcid.org/0000-0002-1585-4514)
- Ana Martinez
- Raquel Aguiar‐Ibáñez (ORCID: https://orcid.org/0000-0002-3839-6966)
- Hannah Penton (ORCID: https://orcid.org/0000-0001-9492-7875)
- Kelly McQuarrie (ORCID: https://orcid.org/0000-0002-2362-1163)
- M. Heisen
- Sayeli Jayade (ORCID: https://orcid.org/0000-0002-3058-9624)
- Laura DiGiovanni (ORCID: https://orcid.org/0000-0002-8654-0117)
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Group Health Cooperative (US)
- The Open Group (GB)
- Pharmerit (Netherlands) (NL)
- Merck Canada Inc. (Canada) (CA)
- Pharmerit (United States) (US)
Publication Details
- Journal
- Future Oncology
- Published
- 2024-12-16
- DOI
- https://doi.org/10.1080/14796694.2024.2436342
- Citations
- 8
- Primary Topic
- Economic and Financial Impacts of Cancer
- Type
- article
- Field-Weighted Citation Impact
- 9.03